• Publications
  • Influence
Montelukast for Chronic Asthma in 6- to 14-Year-Old Children A Randomized, Double-blind Trial
Context.—Leukotrienes are important mediators of asthma by causing bronchoconstriction, mucous secretion, and increased vascular permeability. Studies using compounds that block leukotrienes haveExpand
  • 460
  • 13
Montelukast, a once-daily leukotriene receptor antagonist, in the treatment of chronic asthma: a multicenter, randomized, double-blind trial. Montelukast Clinical Research Study Group.
OBJECTIVES To determine the clinical effect of oral montelukast sodium, a leukotriene receptor antagonist, in asthmatic patients aged 15 years or more. DESIGN Randomized, multicenter, double-blind,Expand
  • 481
  • 9
  • PDF
Montelukast, a leukotriene-receptor antagonist, for the treatment of mild asthma and exercise-induced bronchoconstriction.
BACKGROUND Patients with mild asthma frequently have only exercise-induced bronchoconstriction, a symptom of inadequate control of asthma. We evaluated the ability of montelukast, aExpand
  • 449
  • 8
Improvement of aspirin-intolerant asthma by montelukast, a leukotriene antagonist: a randomized, double-blind, placebo-controlled trial.
Leukotriene antagonists block the proinflammatory actions of leukotrienes (LT) and have been introduced as new treatments for asthma. Conventional therapy with glucocorticosteroids does not inhibitExpand
  • 302
  • 7
  • PDF
The effect of montelukast on rhinitis symptoms in patients with asthma and seasonal allergic rhinitis
SUMMARY Objective: The objective of this study was to evaluate montelukast 10 mg daily as treatment for allergic rhinitis in patients with symptomatic allergic rhinitis and active asthma during theExpand
  • 160
  • 7
Concomitant montelukast and loratadine as treatment for seasonal allergic rhinitis: a randomized, placebo-controlled clinical trial.
BACKGROUND Nasal challenge studies have suggested histamine and cysteinyl leukotrienes are important proinflammatory mediators in allergic rhinitis. This study was designed to determine the efficacyExpand
  • 284
  • 6
Montelukast, a leukotriene receptor antagonist, for the treatment of persistent asthma in children aged 2 to 5 years.
BACKGROUND The greatest prevalence of asthma is in preschool children; however, the clinical utility of asthma therapy for this age group is limited by a narrow therapeutic index, long-termExpand
  • 367
  • 6
  • PDF
Montelukast for treating seasonal allergic rhinitis: a randomized, double‐blind, placebo‐controlled trial performed in the spring
Background Cysteinyl leukotrienes are important proinflammatory mediators believed to have a role in allergic rhinitis.
  • 234
  • 6
Efficacy and tolerability of montelukast alone or in combination with loratadine in seasonal allergic rhinitis: a multicenter, randomized, double-blind, placebo-controlled trial performed in the fall.
BACKGROUND Histamine and cysteinyl leukotrienes seem to be important mediators of allergic rhinitis. OBJECTIVE This multicenter, randomized, double-blind, parallel-group, placebo-controlled trialExpand
  • 188
  • 6
Long‐term asthma control with oral montelukast and inhaled beclomethasone for adults and children 6 years and older
Background Leukotriene receptor antagonists have demonstrated clinical benefits in chronic asthma studies of up to 3 months in duration. The effects of these agents over extended periods of time haveExpand
  • 79
  • 6